Clinical Trials/TCTR20180723002

TCTR20180723002

Recruiting

Phase 4

Safety, humoral and cellular immunity response of double-dose compare to standard-dose hepatitis B revaccinaiton in children after liver transplantaiton

Chulalonkorn University0 sites72 target enrollmentJuly 23, 2018

ConditionsSafety and efficacy of hepatitis B vaccine, standard compare to double dose in short and long term follow-up.infection, bleeding, pain

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Safety and efficacy of hepatitis B vaccine, standard compare to double dose in short and long term follow-up.
Sponsor: Chulalonkorn University
Enrollment: 72
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 23, 2018

End Date

April 30, 2024

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Chulalonkorn University

Eligibility Criteria

Inclusion Criteria

•Participants age less than 18 years old, post liver transplantation, do not on steroid as immunosuppressants, antiHBs antibody less than 100 mIU/m

Exclusion Criteria

•Participant who has serious illness such as fever, loss follow up, on steroid as immunosuppressant therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

BNT162b2 in Thai childreImmunization to prevent COVID-19 infection.COVID-19, vaccination, BNT162b2, children, liver transplant, immunogenicity, safety

TCTR20220708003Chulalongkorn University33

Safety, humoral and cellular immunogenicity after coronavirus disease-19 (COVID-19) vaccination (BNT162b2) in 12 to 18 year-old children after liver transplantatioImmunization to prevent COVID-19 infectionCOVID-19, vaccination, BNT162b2, adolescent, liver transplant, immunogenicity, safety

TCTR20210830002Chulalongkorn university44

Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16

IRCT20190504043464N1Iran University of Medical Sciences200

Not yet recruiting

Study of immunity to flu vaccine.

CTRI/2021/11/037859Christian Medical College Vellore

Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.

RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624